Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, and Puma Biotechnology, Inc.
Navigating Treatment Options for HER2+ Breast Cancer Across the Disease Continuum: An Expert Tumor Board Discussion
Release Date: January 8, 2021
Expiration Date: January 8, 2022
Activity Overview
For patients with HER2+ breast cancer, treatment with HER2-targeted therapies has been shown to improve both short-term and long-term survival, in both early-stage and advanced/metastatic disease. Over the past few years, results from pivotal trials and new regulatory approvals have expanded treatment options, and treatment paradigms are rapidly evolving, in both (neo)adjuvant and metastatic settings. In addition, there are several promising new HER2-targeted agents in late-phase clinical trials, which provide further options for patients with relapsed/refractory disease.
The focus of this activity is the management of patients with HER2+ breast cancer. This educational program will include a series of case presentations to illuminate treatment decisions related to selecting adjuvant therapy for patients with early-stage HER2+ breast cancer, and sequencing lines of treatment for patients with HER2+ metastatic breast cancer based on patient and disease characteristics. This educational activity is an archive of the live, virtual program held at the San Antonio Breast Cancer Symposium on December 9, 2020.
Acknowledgement of Commercial Support
This activity is supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, and Puma Biotechnology, Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This educational program is directed toward medical oncologists. Surgical oncologists, pathologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the management and treatment of breast cancer are also invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Incorporate emerging clinical evidence with HER2-targeted agents into individualized treatment plans for patients with early-stage or advanced/metastatic HER2+ breast cancer
- Review current treatment standards and emerging options for patients with HER2+ breast cancer brain metastases
- Consider ongoing clinical trials of investigational agents for HER2+ breast cancer, and the potential effect of emerging data on current treatment algorithms
- Implement effective strategies to prevent or manage treatment-related adverse events in patients receiving HER2-targeted therapy for breast cancer
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Faculty
Celebrating Woman Chair in Breast Cancer Research
Baylor University Medical Center
Texas Oncology
Chair, Breast Cancer Research Program
The US Oncology Network
Dallas, TX
Disclosures: Consultant: Novartis Pharmaceuticals, AstraZeneca, Celgene Corporation, Eli Lilly and Company, Merck & Co, Pfizer, SeaGen, Inc.
Director, Breast Cancer Oncology Program
Stanford Cancer Institute
Stanford, CA
Disclosures: Consultant: Hoffmann-La Roche/Genentech, Seattle Genetics, Daiichi Sankyo/AstraZeneca; Other: Eli Lilly and Company (spouse).
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Disclosures: Grant Research Support: Pfizer, Merck & Co, Novartis Pharmaceuticals, Eli Lilly and Company, Genentech, OBI Pharma, Odonate Therapeutics, Daiichi Sankyo, Eisai, Seattle Genetics, MacroGenics, Sermonix Pharmaceuticals, Immunomedics; Consultant: Samsung, Puma Biotechnology (limited consulting); Other: Travel: Daiichi Sankyo, Mylan, Pfizer, Merck & Co, AstraZeneca, Novartis Pharmaceuticals, MacroGenics.
Assistant Professor of Medicine
Harvard Medical School
Associate Director, Susan F. Smith Center for Women's Cancers
Director, Clinical Trials, Breast Oncology
Director, Breast Immunotherapy Clinical Research
Senior Physician
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Grant Research Support: Genentech, Eli Lilly and Company, Novartis Pharmaceuticals, AstraZeneca, Merck & Co, Pfizer, Nektar Therapeutics, Exelixis, Bristol Myers Squibb, Eisai, Cyclacel Pharmaceuticals, Immunomedics, Odonate Therapeutics, Seattle Genetics; Consultant: Puma Biotechnology, Nektar Therapeutics, Merck & Co, AstraZeneca, Daiichi Sankyo, NanoString Technologies, Eli Lilly and Company, Pfizer, Novartis Pharmaceuticals, Eisai, Genentech, Immunomedics, Sanofi, Celldex Therapeutics, Paxman, Seattle Genetics, Odonate Therapeutics, Bristol Myers Squibb, G1 Therapeutics, Silverback Therapeutics, AbbVie, Athenex, OncoPep, Samsung Bioepis, Kyowa Kirin Co, CytomX Therapeutics.
The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
